| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | 19.926 | 56.803 | 55.123 | 63.714 | 68.980 | 76.350 |
| Total Income - EUR | - | - | - | - | 19.926 | 56.803 | 55.183 | 63.716 | 69.924 | 76.350 |
| Total Expenses - EUR | - | - | - | - | 7.100 | 18.121 | 25.092 | 24.567 | 33.501 | 34.279 |
| Gross Profit/Loss - EUR | - | - | - | - | 12.827 | 38.682 | 30.091 | 39.148 | 36.423 | 42.071 |
| Net Profit/Loss - EUR | - | - | - | - | 12.229 | 37.068 | 28.436 | 37.237 | 35.724 | 39.780 |
| Employees | - | - | - | - | 0 | 0 | 0 | 0 | 1 | 1 |
Check the financial reports for the company - Neurodiab Năstase S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | 42.123 | 48.105 | 36.043 | 24.518 | 13.305 | 5.614 |
| Current Assets | - | - | - | - | 9.876 | 18.899 | 14.262 | 13.601 | 23.831 | 37.572 |
| Inventories | - | - | - | - | 0 | 868 | 0 | 0 | 0 | 563 |
| Receivables | - | - | - | - | 217 | 424 | 530 | 13 | 1.691 | 2.463 |
| Cash | - | - | - | - | 9.659 | 17.607 | 13.733 | 13.588 | 22.139 | 34.547 |
| Shareholders Funds | - | - | - | - | 12.271 | 49.106 | 49.854 | 37.416 | 35.764 | 39.821 |
| Social Capital | - | - | - | - | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | 39.729 | 17.898 | 451 | 703 | 1.372 | 3.365 |
| Income in Advance | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Neurodiab Năstase S.r.l.